Christina A Bradbury1, Michael R Lappin. 1. Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA. cabrad@colostate.edu
Abstract
OBJECTIVE: To determine whether monthly topical administration of a combination of 10% imidacloprid and 1% moxidectin would lessen flea (Ctenocephalides felis) transmission of Bartonella henselae among cats. DESIGN: Controlled trial. ANIMALS: 18 specific pathogen-free cats housed in 3 groups of 6. PROCEDURES: 3 enclosures were separated by mesh to allow fleas to pass among groups yet prevent cats from contacting one another. One group was inoculated IV with B henselae, and after infection was confirmed, the cats were housed in the middle enclosure. This infected group was flanked by a group that was treated topically with 10% imidacloprid-1% moxidectin monthly for 3 months and by an untreated group. On days 0, 15, 28, and 42, 100 fleas/cat were placed on each of the 6 cats in the B henselae-infected group. Blood samples were collected from all cats weekly for detection of Bartonella spp via PCR assay, bacterial culture, and serologic assay. RESULTS: B henselae infection was confirmed in the cats infected IV and in all untreated cats after flea exposure; none of the cats treated with the imidacloprid-moxidectin combination became infected. CONCLUSIONS AND CLINICAL RELEVANCE: In this setting, monthly topical administration of 10% imidacloprid-1% moxidectin reduced flea infestation, compared with infestation in untreated cats, and thus prevented flea transmission of B henselae to treated cats. Regular monthly use of this flea control product in cats may lessen the likelihood of humans acquiring B henselae infection.
OBJECTIVE: To determine whether monthly topical administration of a combination of 10% imidacloprid and 1% moxidectin would lessen flea (Ctenocephalides felis) transmission of Bartonella henselae among cats. DESIGN: Controlled trial. ANIMALS: 18 specific pathogen-free cats housed in 3 groups of 6. PROCEDURES: 3 enclosures were separated by mesh to allow fleas to pass among groups yet prevent cats from contacting one another. One group was inoculated IV with B henselae, and after infection was confirmed, the cats were housed in the middle enclosure. This infected group was flanked by a group that was treated topically with 10% imidacloprid-1% moxidectin monthly for 3 months and by an untreated group. On days 0, 15, 28, and 42, 100 fleas/cat were placed on each of the 6 cats in the B henselae-infected group. Blood samples were collected from all cats weekly for detection of Bartonella spp via PCR assay, bacterial culture, and serologic assay. RESULTS: B henselae infection was confirmed in the cats infected IV and in all untreated cats after flea exposure; none of the cats treated with the imidacloprid-moxidectin combination became infected. CONCLUSIONS AND CLINICAL RELEVANCE: In this setting, monthly topical administration of 10% imidacloprid-1% moxidectin reduced flea infestation, compared with infestation in untreated cats, and thus prevented flea transmission of B henselae to treated cats. Regular monthly use of this flea control product in cats may lessen the likelihood of humans acquiring B henselae infection.
Authors: Emilie Bouhsira; Michel Franc; Emmanuel Lienard; Corinne Bouillin; Christelle Gandoin; Thomas Geurden; Csilla Becskei; Philippe Jacquiet; Anne Thomas; Henri Jean Boulouis Journal: Parasitol Res Date: 2015-01-14 Impact factor: 2.289
Authors: K J Wardrop; A Birkenheuer; M C Blais; M B Callan; B Kohn; M R Lappin; J Sykes Journal: J Vet Intern Med Date: 2016 Jan-Feb Impact factor: 3.333
Authors: Sandra Schorderet-Weber; Sandra Noack; Paul M Selzer; Ronald Kaminsky Journal: Int J Parasitol Drugs Drug Resist Date: 2017-01-30 Impact factor: 4.077
Authors: Michael R Lappin; Wendell L Davis; Jennifer R Hawley; Melissa Brewer; Arianne Morris; Dorothee Stanneck Journal: Parasit Vectors Date: 2013-01-25 Impact factor: 3.876